Nasdaq
$34.22▼ 1.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.25BShares out 95.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.8After-hours26.10.09 08:034Ownership#●●●#●●●
IDEAYA Biosciences, Inc.
Insider Hata Yujiro of IDEAYA Biosciences completed a transaction involving the sale of company shares on October 6, 2026. This filing serves as an official SEC notification regarding the change in the insider's beneficial ownership.…more
$34.22-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:13144Ownership
IDEAYA Biosciences, Inc.
Insider Yujiro S. Hata of IDEAYA Biosciences, Inc. has filed an SEC Form 144 to report a proposed sale of company securities. This is a standard regulatory filing disclosing an insider's plan to dispose of shares.…more
$34.22-1.38%vs prev closeView filingShare - 8.4After-hours26.08.05 05:0510-QEarnings
IDEAYA Biosciences, Inc.
IDEAYA Biosciences는 2026년 6월 30일 기준 분기 보고서(10-Q)를 제출하였으며, 2026년 7월 31일 기준 발행 주식 수는 96,489,484주입니다. 또한 회사는 2026년 6월 16일부로 사외이사 보상 프로그램을 개정하여 신규 선임 이사에게 40,000주의 스톡옵션을 부여하고 기존 이사에게는 연간 20,000주의 스톡옵션을 부여하는 보상 체계를 확정했습니다.…more
$34.22-1.38%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 19:07#●●●#●●●
IDEAYA to Present Updated Melanoma Drug Data at Upcoming ESMO Congress
IDEAYA Biosciences will present updated clinical data for its melanoma drug darovasertib at the upcoming ESMO Congress. As the presentation focuses on ongoing trial data without confirmed efficacy results, the impact remains neutral.…more
$34.22-1.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9Pre-market26.09.09 19:18
●●●●●●●● ●●●●● ●●●●●●
IDEAYA Biosciences has dosed the first patient in its Phase 3 registrational trial for darovasertib as an adjuvant therapy for primary uveal melanoma. As there are currently no approved adjuvant treatments for this condition, this trial marks a significant milestone in the company's clinical development.…more
$34.22-1.38%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 19:12
●●●●●●●● ●●●●● ●●●●●●
IDEAYA Biosciences will host an Investor R&D Day in London this November to present new preclinical data and development strategies for pancreatic cancer. The company also announced its participation in several major investor conferences throughout September.…more
$34.22-1.38%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report